ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2021 and some content may be unavailable. To unlock all content for 2021, please visit the archives.

Abstract: PO0963

Thirty Days of Maintenance Peritoneal Dialysis Using a Sorbent-Based Automated Wearable Artificial Kidney (AWAK) PD Device in a Porcine Model

Session Information

Category: Dialysis

  • 702 Dialysis: Home Dialysis and Peritoneal Dialysis

Authors

  • Foo, Marjorie Wai Yin, Singapore General Hospital, Singapore, Singapore
  • Htay, Htay, Singapore General Hospital, Singapore, Singapore
  • Brown, Edwina A., Hammersmith Hospital, London, London, United Kingdom
  • Chirumarry, Sridhar, AWAK Technologies Pte Ltd, Singapore, Singapore
  • Pawlak, Marcin, AWAK Technologies Pte Ltd, Singapore, Singapore
  • Huda, Siti Noor, AWAK Technologies Pte Ltd, Singapore, Singapore
  • Lim, Jason Tze chern, AWAK Technologies Pte Ltd, Singapore, Singapore
  • Singh, Sanjay, AWAK Technologies Pte Ltd, Singapore, Singapore
  • Gori, Mandar, AWAK Technologies Pte Ltd, Singapore, Singapore
  • Venkataraya, Suresha Belur, AWAK Technologies Pte Ltd, Singapore, Singapore
  • Jain, Arsh, Western University, London, Ontario, Canada
Background

In sorbent-based PD, spent dialysate is processed and clean dialysate is re-introduced into the abdomen. Our aim was to determine if AWAK dialysis can maintain euvolemia and biochemistry for 30 days in a porcine model.

Methods

The study was conducted in a 5/6 nephrectomised pig (Sus Scrofa, male). Post nephrectomy, the animal was treated with CAPD (14 weeks) before commencing sorbent-based PD for 7 hour per day with initial fill of 2L 1.5% Dianeal for 30 consecutive days. Thereafter, the animal was maintained on standard of care (SOC) for 3 days (5x2L exchanges over 10 hour APD, with 1L last fill, 2.5% Dianeal).

Results

Stable serum concentration of toxins, electrolytes and inflammatory markers were noted during AWAK therapy (Table); with no significant change after switch to SOC. pH of regenerated dialysate was consistent with biocompatible solutions (figure 1) and appropriate change in ultrafiltration was observed in response to glucose infusion (figure 2).

Conclusion

AWAK PD therapy successfully treated a CKD animal model for 30 days, without adverse impact on volume status or clinical parameters. Future long-term human studies are needed for device enhancement.

 Day 1 [AWAK]Day 30 [AWAK]Mean (SD) [AWAK]Median (IQR) [AWAK]Mean (SD) [SOC]p-value#
Urea (mmol/L)7.57.98.5 (0.6)8.6 (1)8.9 (0.72)0.29
Creatinine (μmol/L)267.5287.5282.5 (9.9)283 (14.4)296.6 (4.8)0.38
Phosphate (mmol/L)2.572.722.6 (0.1)2.6 (0.2)2.6 (0.04)0.83
B2M (μg/L)317.5266.5293.6 (17)297.5 (27.7)285.3 (15.0)0.24
Sodium (mmol/L)142.5145144.6 (1.4)144.8(1.5)145.6 (1.52)0.87
Potassium (mmol/L)4.44.84.6 (0.18)4.6 (0.36)4.8 (0.2)0.19
Chloride (mmol/L)100101101.2 (1.0)101 (1.4)100.1 (0.2)0.01
Bicarbonate (mmol/L)34.634.134 (1.0)34 (1.2)34.8 (1.55)0.97
Calcium (mmol/L)2.412.452.4 (0.04)2.4 (0.1)2.47 (0.02)0.19
Magnesium (mmol/L)1.091.131.1 (0.05)1.1 (0)1.14 (0.04)0.29
CRP0.450.350.36 (0.08)0.4 (0.1)0.28 (0.05)0.25
WBC (x10^9) g/L13.38.89.6 (1.7)9.4 (0.9)8.85 (0.20)0.84
Hb (g/dL)8.411.410.7 (0.8)10.9 (1.0)11.2 (0.65)0.93

#last 3 days data of AWAK and SOC compared

Funding

  • Commercial Support – AWAK Technologies Pte Ltd